CervoMed Inc
CRVO9.800USD
+0.970+10.99%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
85.29MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über CervoMed Inc Unternehmen
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. It is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.
Unternehmensinformationen
BörsenkürzelCRVO
Name des UnternehmensCervoMed Inc
IPO-datumNov 09, 2016
CEOMr. John J. Alam, M.D.
Anzahl der mitarbeiter15
WertpapierartOrdinary Share
GeschäftsjahresendeNov 09
Addresse20 Park Plaza, Suite 424
StadtBOSTON
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl02116
Telefon16177444400
Websitehttps://cervomed.com/
BörsenkürzelCRVO
IPO-datumNov 09, 2016
CEOMr. John J. Alam, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.06M
--
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
730.79K
+0.17%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Mr. William R. Elder
Mr. William R. Elder
Chief Financial Officer, General Counsel, Corporate Secretary
Chief Financial Officer, General Counsel, Corporate Secretary
--
--
Dr. Marwan Noel Sabbagh, M.D.
Dr. Marwan Noel Sabbagh, M.D.
Independent Director
Independent Director
--
--
Dr. Claudia Ordonez, M.D.
Dr. Claudia Ordonez, M.D.
Senior Vice President - Medical Science
Senior Vice President - Medical Science
--
--
Dr. Marco Verwijs, Ph.D.
Dr. Marco Verwijs, Ph.D.
Executive Vice President - Technical Operations
Executive Vice President - Technical Operations
--
--
Dr. Robert J. Cobuzzi, Jr.
Dr. Robert J. Cobuzzi, Jr.
Director
Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.06M
--
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
730.79K
+0.17%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Mr. William R. Elder
Mr. William R. Elder
Chief Financial Officer, General Counsel, Corporate Secretary
Chief Financial Officer, General Counsel, Corporate Secretary
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Boger (Joshua S)
12.15%
AWM Investment Company, Inc.
9.92%
Gregoire (Sylvie L.)
8.40%
Alam (John J)
8.40%
The Vanguard Group, Inc.
4.35%
Other
56.79%
Aktionäre
Aktionäre
Anteil
Boger (Joshua S)
12.15%
AWM Investment Company, Inc.
9.92%
Gregoire (Sylvie L.)
8.40%
Alam (John J)
8.40%
The Vanguard Group, Inc.
4.35%
Other
56.79%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
33.43%
Investment Advisor/Hedge Fund
14.17%
Investment Advisor
10.36%
Research Firm
1.60%
Hedge Fund
0.09%
Bank and Trust
0.06%
Pension Fund
0.02%
Other
40.27%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
117
5.20M
59.72%
-1.49M
2025Q1
117
5.20M
61.51%
-1.51M
2024Q4
109
4.40M
53.34%
-2.51M
2024Q3
92
6.43M
77.88%
-414.79K
2024Q2
78
6.37M
77.13%
+108.27K
2024Q1
52
5.40M
90.18%
+2.52M
2023Q4
54
3.10M
54.81%
+657.18K
2023Q3
54
3.32M
58.71%
+3.16M
2023Q2
46
125.98K
9.26%
-42.41K
2023Q1
54
143.15K
10.53%
-17.76K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Boger (Joshua S)
1.06M
12.15%
--
--
Apr 24, 2025
AWM Investment Company, Inc.
863.20K
9.92%
+863.20K
--
Mar 31, 2025
Gregoire (Sylvie L.)
730.79K
8.4%
-1.25K
-0.17%
Apr 24, 2025
Alam (John J)
730.79K
8.4%
+1.25K
+0.17%
Apr 24, 2025
The Vanguard Group, Inc.
378.66K
4.35%
-4.83K
-1.26%
Mar 31, 2025
Zavrl (Frank E.)
353.01K
4.06%
--
--
Apr 24, 2025
BlackRock Institutional Trust Company, N.A.
321.48K
3.69%
+24.03K
+8.08%
Mar 31, 2025
Morgan Stanley & Co. LLC
130.60K
1.5%
+87.90K
+205.86%
Mar 31, 2025
Geode Capital Management, L.L.C.
116.48K
1.34%
+1.65K
+1.43%
Mar 31, 2025
State Street Global Advisors (US)
112.06K
1.29%
-4.20K
-3.61%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Health Innovation Active ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Anteil0.01%
iShares Russell 2000 Growth ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
iShares Health Innovation Active ETF
Anteil0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Apr 18, 2022
Merger
50<1
Apr 18, 2022
Merger
50<1
Datum
Art
Verhältnis
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Aug 16, 2023
Merger
1.5<1
Apr 18, 2022
Merger
50<1
Apr 18, 2022
Merger
50<1
Apr 18, 2022
Merger
50<1
Apr 18, 2022
Merger
50<1
